Special considerations in the use of cardiovascular drugs.
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D000925:Anticoagulants / Q000009:adverse effects; D002301:Cardiac Glycosides / Q000009:adverse effects; D002317:Cardiovascular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004206:Disopyramide / Q000009:adverse effects; D004232:Diuretics / Q000009:adverse effects; D005260:Female; D005333:Fetus / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy; D011342:Procainamide / Q000009:adverse effects; D011433:Propranolol / Q000009:adverse effects; D011802:Quinidine / Q000009:adverse effects
D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D002301:Cardiac Glycosides; D002317:Cardiovascular Agents; D004232:Diuretics; D011433:Propranolol; D004206:Disopyramide; D011802:Quinidine; D011342:Procainamide